Recruiting × Lymphoma, Follicular × Other hematologic neoplasm × Clear all CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
572 enrolled
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Phase NA Recruiting
200 enrolled
Aquarius
Recruiting
550 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/2 Recruiting
100 enrolled
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting
30 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 Recruiting
60 enrolled
Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 Recruiting
98 enrolled
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Phase 1 Recruiting
27 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Recruiting
200 enrolled
TITANium
Phase 1/2 Recruiting
174 enrolled
RUBIN
Recruiting
2,950 enrolled
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
Phase 1 Recruiting
340 enrolled
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Phase 1 Recruiting
154 enrolled
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Recruiting
36 enrolled
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 Recruiting
120 enrolled
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
120 enrolled
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Recruiting
500 enrolled
OPAL
Phase 1/2 Recruiting
144 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 Recruiting
46 enrolled
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 Recruiting
60 enrolled
ARIADNE
Recruiting
705 enrolled
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Recruiting
45 enrolled
HYCVA
Phase NA Recruiting
50 enrolled
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Phase 1 Recruiting
148 enrolled
BAH241
Phase 1/2 Recruiting
75 enrolled
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
37 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 Recruiting
56 enrolled
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Phase NA Recruiting
40 enrolled
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 Recruiting
300 enrolled
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Recruiting
200 enrolled
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Phase 1/2 Recruiting
146 enrolled
SANGUINE
Recruiting
3,000 enrolled
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
248 enrolled
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Phase 2 Recruiting
30 enrolled
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
Phase 1/2 Recruiting
68 enrolled